Shopping Cart
- Remove All
- Your shopping cart is currently empty
ACT 178882 is a novel Renin inhibitor with an IC50 of 1.4 nM.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $3,020 | 10-14 weeks | |
50 mg | $3,980 | 10-14 weeks | |
100 mg | $5,500 | 10-14 weeks |
Description | ACT 178882 is a novel Renin inhibitor with an IC50 of 1.4 nM. |
Targets&IC50 | Renin:1.4 nM |
In vitro | The median time to Cmax (tmax) for ACT 178882 is prolonged from 3.5 to 5.0 h by diltiazem whereas its apparent terminal half-life (t?) is unaffected by diltiazem, 22.9 and 24.2 h for treatments A and B, respectively. Using treatment A as reference, the geometric mean ratio (90% CI) is 1.62 (1.36 to 1.94) for Cmax and 2.02 (1.75 to 2.34) for AUC∞, indicating a significant interaction between ACT 178882 and diltiazem[2]. |
Molecular Weight | 647.03 |
Formula | C33H38Cl3N3O4 |
Cas No. | 1007392-69-9 |
Relative Density. | 1.33 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.